Literature DB >> 30819078

Donepezil Derivatives Targeting Amyloid-β Cascade in Alzheimer's Disease.

Eva Mezeiova1,2,3, Katarina Chalupova1,2,4, Eugenie Nepovimova4, Lukas Gorecki1,3, Lukas Prchal1, David Malinak1,4, Kamil Kuca1,4, Ondrej Soukup1,2,3, Jan Korabecny1,2,3.   

Abstract

Alzheimer's Disease (AD) is a neurodegenerative disorder with an increasing impact on society. Because currently available therapy has only a short-term effect, a huge number of novel compounds are developed every year exploiting knowledge of the various aspects of AD pathophysiology. To better address the pathological complexity of AD, one of the most extensively pursued strategies by medicinal chemists is based on Multi-target-directed Ligands (MTDLs). Donepezil is one of the currently approved drugs for AD therapy acting as an acetylcholinesterase inhibitor. In this review, we have made an extensive literature survey focusing on donepezil-derived MTDL hybrids primarily targeting on different levels cholinesterases and amyloid beta (Aβ) peptide. The targeting includes direct interaction of the compounds with Aβ, AChE-induced Aβ aggregation, inhibition of BACE-1 enzyme, and modulation of biometal balance thus impeding Aβ assembly. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Acetylcholinesterase; Alzheimer`s disease; amyloid-β; beta-secretase 1; biometal; butyrylcholinesterase; multitargetzzm321990directed ligands; neuroprotection.

Year:  2019        PMID: 30819078     DOI: 10.2174/1567205016666190228122956

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  5 in total

Review 1.  Alzheimer's disease therapy based on acetylcholinesterase inhibitor/blocker effects on voltage-gated potassium channels.

Authors:  Xian-Tao Li
Journal:  Metab Brain Dis       Date:  2022-01-31       Impact factor: 3.584

2.  A Novel Multifunctional 5,6-Dimethoxy-Indanone-Chalcone-Carbamate Hybrids Alleviates Cognitive Decline in Alzheimer's Disease by Dual Inhibition of Acetylcholinesterase and Inflammation.

Authors:  Chan Liu; Zhipei Sang; Hong Pan; Qin Wu; Yu Qiu; Jingshan Shi
Journal:  Front Aging Neurosci       Date:  2022-07-04       Impact factor: 5.702

3.  NeuroProtect, a Candidate Formula From Traditional Chinese Medicine, Attenuates Amyloid-β and Restores Synaptic Structures in APP/PS1 Transgenic Mice.

Authors:  Yan Tan; Xu Wang; Jiani Zhang; Huawei Zhang; Haiyan Li; Tiantian Peng; Weihang Chen; Peng Wei; Zhaoheng Liu; Fang He; Jiao Li; Haimin Ding; Na Li; Zhaoyang Wang; Zhenqiang Zhang; Qian Hua
Journal:  Front Pharmacol       Date:  2022-05-02       Impact factor: 5.988

Review 4.  Effects of Linkers and Substitutions on Multitarget Directed Ligands for Alzheimer's Diseases: Emerging Paradigms and Strategies.

Authors:  Narayanaperumal Pravin; Krzysztof Jozwiak
Journal:  Int J Mol Sci       Date:  2022-05-29       Impact factor: 6.208

5.  Design, Synthesis, and In Vitro Evaluation of Hydroxybenzimidazole-Donepezil Analogues as Multitarget-Directed Ligands for the Treatment of Alzheimer's Disease.

Authors:  Sílvia Chaves; Simonetta Resta; Federica Rinaldo; Marina Costa; Romane Josselin; Karolina Gwizdala; Luca Piemontese; Vito Capriati; A Raquel Pereira-Santos; Sandra M Cardoso; M Amélia Santos
Journal:  Molecules       Date:  2020-02-22       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.